Molecular Formula | C24H30ClN3O5 |
Molar Mass | 475.9651 |
Appearance | powder |
Color | white to beige |
Storage Condition | -20°C |
In vitro study | ITF2357 acts on LPS-stimulated cultured human peripheral blood mononuclear cells (PBMCs). ITF2357 reduces the release of TNFα,IL-1α,IL-1β and IFNγ with an IC50 of 10-25 nM. The combination of ITF2357 and IL-12 and IL-18 reduced IFNγ and IL-6 production with an IC50 of 12.5-25 nM. ITF2357 acts on multiple myeloma (MM) cell lines (RPMI8226,NCI-H929,JJN3,KMS 11,KMS 12,KMS 18, and KMS 20) and acute myeloid leukemia (AML) cell lines (HL-60,THP-1,U937,KASUMI,KG-1, and TF-1) were cytotoxic with a mean IC50 of 200 nM. ITF2357 activated the internal apoptotic pathway, up-regulated p21, down-regulated Bcl-2 and Mcl-1. ITF2357 acts on mesenchymal stem cells (MSCs) and inhibits IL-6,VEGF, and IFNγ production by 80-95%. In the presence of inflammation, ITF2357 favors beta cell survival. ITF2357 at 25 and 250 nM increased islet cell viability, enhanced insulin secretion, inhibited MIP-1α and MIP-2 release, decreased NO production, and decreased apoptosis rate. ITF2357 acts on LPS-stimulated cultured human peripheral blood mononuclear cells (PBMCs). ITF2357 reduces the release of TNFα,IL-1α,IL-1β and IFNγ with an IC50 of 10-25 nM. The combination of ITF2357 and IL-12 and IL-18 reduced IFNγ and IL-6 production with an IC50 of 12.5-25 nM. ITF2357 acts on multiple myeloma (MM) cell lines (RPMI8226,NCI-H929,JJN3,KMS 11,KMS 12,KMS 18, and KMS 20) and acute myeloid leukemia (AML) cell lines (HL-60,THP-1,U937,KASUMI,KG-1, and TF-1) were cytotoxic with a mean IC50 of 200 nM. ITF2357 activated the internal apoptotic pathway, up-regulated p21, down-regulated Bcl-2 and Mcl-1. ITF2357 acts on mesenchymal stem cells (MSCs) and inhibits IL-6,VEGF, and IFNγ production by 80-95%. In the presence of inflammation, ITF2357 favors beta cell survival. ITF2357 at 25 and 250 nM increased islet cell viability, enhanced insulin secretion, inhibited MIP-1α and MIP-2 release, decreased NO production, and decreased apoptosis rate. |
In vivo study | ITF2357 at a dose of 1.0-10 mg/kg in mice reduced LPS-induced serum TNFα and IFNγ by more than 50%. ITF2357 does not inhibit the cytokine induced by CD3 antibody in peripheral blood mononuclear cells of mice. ITF2357 acts on concanavalin A- induced hepatitis at A dose of 1 or 5 mg/kg, Star reduces liver damage. ITF2357 acts on SCID mice injected with AML-PS cell line in vivo at a dose of 10 mg/kg, and the star prolongs life. ITF2357 at a dose of 10 mg/kg acts on a closed craniocerebral injury (CHI) rat model to promote neurobehavioral recovery, reduce neuronal deterioration, reduce the degree of injury, and induce glial apoptosis. ITF2357 at a dose of 1.0-10 mg/kg in mice reduced LPS-induced serum TNFα and IFNγ by more than 50%. ITF2357 does not inhibit the cytokine induced by CD3 antibody in peripheral blood mononuclear cells of mice. ITF2357 acts on concanavalin A- induced hepatitis at A dose of 1 or 5 mg/kg, Star reduces liver damage. ITF2357 acts on SCID mice injected with AML-PS cell line in vivo at a dose of 10 mg/kg, and the star prolongs life. ITF2357 at a dose of 10 mg/kg acts on a closed craniocerebral injury (CHI) rat model to promote neurobehavioral recovery, reduce neuronal deterioration, reduce the degree of injury, and induce glial apoptosis. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.101 ml | 10.505 ml | 21.01 ml |
5 mM | 0.42 ml | 2.101 ml | 4.202 ml |
10 mM | 0.21 ml | 1.05 ml | 2.101 ml |
5 mM | 0.042 ml | 0.21 ml | 0.42 ml |